|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bauman G, Fisher B, Watling C, Cairncross
JG and Macdonald D: Adult supratentorial low-grade glioma:
long-term experience at a single institution. Int J Radiat Oncol
Biol Phys. 75:1401–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van den Bent MJ, Afra D, de Witte O, Ben
Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L,
Pierart M, Mirimanoff R and Karim AB: Long-term efficacy of early
versus delayed radiotherapy for low-grade astrocytoma and
oligodendroglioma in adults: the EORTC 22845 randomised trial.
Lancet. 366:985–990. 2005.PubMed/NCBI
|
|
4
|
Shaw EG, Wang M, Coons S, Brachman D,
Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR and Mehta MP:
Final report of Radiation Therapy Oncology Group (RTOG) protocol
9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and
vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J
Clin Oncol (ASCO Meeting abst). 26:20062008.
|
|
5
|
Bauman G, Lote K, Larson D, Stalpers L,
Leighton C, Fisher B, Wara W, MacDonald D, Stitt L and Cairncross
JG: Pretreatment factors predict overall survival for patients with
low-grade glioma: a recursive partitioning analysis. Int J Radiat
Oncol Biol Phys. 45:923–929. 1999. View Article : Google Scholar
|
|
6
|
Chang EF, Smith JS, Chang SM, Lamborn KR,
Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS and
McDermott MM: Preoperative prognostic classification system for
hemispheric low-grade gliomas in adults. J Neurosurg. 109:817–824.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pignatti F, van den Bent M, Curran D,
Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M,
Vecht C and Karim AB: Prognostic factors for survival in adult
patients with cerebral low-grade glioma. J Clin Oncol.
20:2076–2084. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schiff D, Brown PD and Giannini C: Outcome
in adult low-grade glioma: the impact of prognostic factors and
treatment. Neurology. 69:1366–1373. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith JS, Chang EF, Lamborn KR, Chang SM,
Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW and Berger
MS: Role of extent of resection in the long-term outcome of
low-grade hemispheric gliomas. J Clin Oncol. 26:1338–1345. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith JS, Alderete B, Minn Y, Borell TJ,
Perry A, Mohapatra G, Hosek SM, Kimmel D, O’Fallon J, Yates A, et
al: Localization of common deletion regions on 1p and 19q in human
gliomas and their association with histological subtype. Oncogene.
18:4144–4152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watanabe T, Nobusawa S, Kleihues P and
Ohgaki H: IDH1 mutations are early events in the development of
astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith JS, Perry A, Borell TJ, Lee HK,
O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW
and Jenkins RB: Alterations of chromosome arms 1p and 19q as
predictors of survival in oligodendrogliomas, astrocytomas, and
mixed oligoastrocytomas. J Clin Oncol. 18:636–645. 2000.PubMed/NCBI
|
|
13
|
Mariani L, Deiana G, Vassella E, Fathi AR,
Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger
M and Reinert MM: Loss of heterozygosity 1p36 and 19q13 is a
prognostic factor for overall survival in patients with diffuse WHO
grade 2 gliomas treated without chemotherapy. J Clin Oncol.
24:4758–4763. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ichimura K, Vogazianou AP, Liu L, Pearson
DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG and
Collins VP: 1p36 is a preferential target of chromosome 1 deletions
in astrocytic tumours and homozygously deleted in a subset of
glioblastomas. Oncogene. 27:2097–2108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vogazianou AP, Chan R, Backlund LM,
Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP and Ichimura
K: Distinct patterns of 1p and 19q alterations identify subtypes of
human gliomas that have different prognoses. Neurooncology.
12:664–678. 2010.PubMed/NCBI
|
|
16
|
Hartmann C, Hentschel B, Tatagiba M,
Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T,
von Deimling A, Loeffler M and Weller M: Molecular markers in
low-grade gliomas: predictive or prognostic? Clin Cancer Res.
17:4588–4599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balss J, Meyer J, Mueller W, Korshunov A,
Hartmann C and von Deimling A: Analysis of the IDH1 codon 132
mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Houillier C, Wang X, Kaloshi G, Mokhtari
K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A,
Laigle-Donadey F, et al: IDH1 or IDH2 mutations predict longer
survival and response to temozolomide in low-grade gliomas.
Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Metellus P, Coulibaly B, Colin C, de Paula
AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K,
Wang XW, et al: Absence of IDH mutation identifies a novel
radiologic and molecular subtype of WHO grade II gliomas with
dismal prognosis. Acta Neuropathol. 120:719–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YH, Nobusawa S, Mittelbronn M, Paulus
W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y,
et al: Molecular classification of low-grade diffuse gliomas. Am J
Pathol. 177:2708–2714. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mukasa A, Takayanagi S, Saito K, Shibahara
J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K and
Saito N: Significance of IDH mutations varies with tumor histology,
grade, and genetics in Japanese glioma patients. Cancer Sci.
103:587–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Camelo-Piragua S, Jansen M, Ganguly A, Kim
JC, Louis DN and Nutt CL: Mutant IDH1-specific immunohistochemistry
distinguishes diffuse astrocytoma from astrocytosis. Acta
Neuropathol. 119:509–511. 2010. View Article : Google Scholar
|
|
24
|
Hartmann C, Meyer J, Balss J, Capper D,
Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et
al: Type and frequency of IDH1 and IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: a study of
1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franco-Hernandez C, Martinez-Glez V, de
Campos JM, Isla A, Vaquero J, Gutierrez M, Casartelli C and Rey JA:
Allelic status of 1p and 19q in oligodendrogliomas and
glioblastomas: multiplex ligation-dependent probe amplification
versus loss of heterozygosity. Cancer Genet Cytogenet. 190:93–96.
2009. View Article : Google Scholar
|
|
26
|
Schouten JP, McElgunn CJ, Waaijer R,
Zwijnenburg D, Diepvens F and Pals G: Relative quantification of 40
nucleic acid sequences by multiplex ligation-dependent probe
amplification. Nucleic Acids Res. 30:e572002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van den Bent MJ, Dubbink HJ, Marie Y,
Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe
D, Idbaih A, et al: IDH1 and IDH2 mutations are prognostic but not
predictive for outcome in anaplastic oligodendroglial tumors: a
report of the European Organization for Research and Treatment of
Cancer Brain Tumor Group. Clin Cancer Res. 16:1597–1604.
2010.PubMed/NCBI
|
|
28
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang
P, Yu W, Li Z, Gong L, Peng Y, et al: Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce
HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reitman ZJ and Yan H: Isocitrate
dehydrogenase 1 and 2 mutations in cancer: alterations at a
crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmadi R, Dictus C, Hartmann C, Zurn O,
Edler L, Hartmann M, Combs S, Herold-Mende C, Wirtz CR and
Unterberg A: Long-term outcome and survival of surgically treated
supratentorial low-grade glioma in adult patients. Acta Neurochir.
151:1359–1365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Daniels TB, Brown PD, Felten SJ, Wu W,
Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D and Shaw EG:
Validation of EORTC prognostic factors for adults with low-grade
glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol
Phys. 81:218–224. 2011. View Article : Google Scholar : PubMed/NCBI
|
